Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

Also called NCT05469659

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05469659
  • jRCT jRCTs031210339
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05469659. Randomized; no masking; primary purpose treatment. Start 2021-09-22 (actual); primary completion 2025-10-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD)
Acronym
TRUTH-DKD
Condition
T2DM (Type 2 Diabetes Mellitus)
Condition
Metformin
Intervention (Drug)
Tofogliflozin
Intervention (Drug)
Metformin
Lead sponsor
Shinshu University (class: other)
Collaborator
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05469659
Content hash
c45ff34f7f74f625e4690914cd9d02bc422573ff20b7cb23b8eac10be2fea270